Zacks Investment Research
27 Jul 2026, 13:50 UTC · 1h ago
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
27 Jul 2026, 13:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Abbott Laboratories raised its full-year adjusted earnings guidance to $5.45-$5.60 per share from $5.38-$5.58. — Upward revisions to annual guidance typically trigger positive sentiment and price appreciation.
+0.40Abbott's second-quarter adjusted earnings were $1.31 per share, a 4% year-over-year increase, with sales rising 13% to $12.59 billion. — A beat in quarterly earnings and sales demonstrates operational strength and growth.
+0.30Second-quarter interest expense surged to $299 million from $50 million a year earlier due to the Exact Sciences acquisition. — Significant increases in interest costs can squeeze net margins and create financing pressure.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
The stock's price target of $108 implies less than 5% upside from its current price of $103.06. — Limited projected upside suggests the stock is fairly valued, reducing the catalyst for a strong rally.
Comparable sales in Abbott's Nutrition segment declined by 3.6%. — Weakness in a specific business segment acts as a drag on overall growth profiles.
-0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
54m ago
